ExeGi Pharma Announces Partnership With TannerLAC to Bring Visbiome® High Potency Probiotic to Mexico standard
Rockville, M.D., and Charlotte, N.C., April 12, 2023 – ExeGi Pharma LLC (“ExeGi”), a leading developer of live biotherapeutic drugs and probiotics, has announced a partnership with TannerLAC, Inc. (“TannerLAC”), a division of Tanner Pharma Group, to distribute Visbiome in Mexico. Visbiome is a high potency probiotic medical food designed to manage microbial imbalances associated with medical conditions such as irritable bowel syndrome (IBS), Ulcerative Colitis (UC), Antibiotic-Associated Diarrhea (AAD), Pouchitis, and Hepatic Encephalopathy (HE). With a proven track record in over 80 human clinical trials performed over the past 20 years, Visbiome is the most extensively researched multi-strain probiotic available. TannerLAC provides pharmaceutical, biotech, and healthcare companies with a single-point partner for the commercialization of their products in challenging international markets. Under ...
Continue Reading